PMID- 29407048
OWN - NLM
STAT- MEDLINE
DCOM- 20190109
LR  - 20190109
IS  - 1558-4410 (Electronic)
IS  - 0889-8529 (Linking)
VI  - 47
IP  - 1
DP  - 2018 Mar
TI  - Personalizing Glucose-Lowering Therapy in Patients with Type 2 Diabetes and 
      Cardiovascular Disease.
PG  - 137-152
LID - S0889-8529(17)30116-0 [pii]
LID - 10.1016/j.ecl.2017.10.011 [doi]
AB  - Twelve drug categories are marketed in the United States to lower blood glucose 
      concentrations in type 2 diabetes mellitus (T2DM). After metformin, there is 
      disagreement about the optimal next choice for combination therapy. Guidelines 
      advise balancing potency, risks, benefits, and costs. For T2DM and cardiovascular 
      disease (CVD), emerging evidence suggests that certain options may have specific 
      advantages. Specific members of the thiazolidinedione, sodium-glucose 
      cotransporter-2 inhibitor, and glucagon-like peptide-1 receptor agonist classes 
      have been associated with significant reductions in major adverse cardiovascular 
      events, generally in those with established CVD. A personalized approach should 
      consider these evidence-based therapies to optimize clinical outcomes.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Inzucchi, Silvio E
AU  - Inzucchi SE
AD  - Yale Endocrinology, Fitkin 106, Box 208020, New Haven, CT 06520-8020, USA. 
      Electronic address: silvio.inzucchi@yale.edu.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Endocrinol Metab Clin North Am
JT  - Endocrinology and metabolism clinics of North America
JID - 8800104
RN  - 0 (Hypoglycemic Agents)
SB  - IM
MH  - Cardiovascular Diseases/*drug therapy/metabolism
MH  - Diabetes Mellitus, Type 2/*drug therapy/metabolism
MH  - Humans
MH  - Hypoglycemic Agents/administration & dosage/adverse effects/*pharmacology
OTO - NOTNLM
OT  - Cardiovascular disease
OT  - Glucose-lowering therapy
OT  - Type 2 diabetes
EDAT- 2018/02/07 06:00
MHDA- 2019/01/10 06:00
CRDT- 2018/02/07 06:00
PHST- 2018/02/07 06:00 [entrez]
PHST- 2018/02/07 06:00 [pubmed]
PHST- 2019/01/10 06:00 [medline]
AID - S0889-8529(17)30116-0 [pii]
AID - 10.1016/j.ecl.2017.10.011 [doi]
PST - ppublish
SO  - Endocrinol Metab Clin North Am. 2018 Mar;47(1):137-152. doi: 
      10.1016/j.ecl.2017.10.011.